Transition Metal Complexes for Cancer Therapy and DNA Interaction
This community focuses on the synthesis and structural characterization of metal-based compounds, specifically copper, platinum, and ruthenium complexes, designed to interact with DNA and inhibit cancer cell growth.
The research centers on designing ligands, frequently Schiff bases, to create stable metal complexes with defined crystal structures. These compounds are evaluated for their anticancer activity against specific cell lines, including ovarian, breast, lung, and cervical cancer. A significant portion of the work addresses cisplatin resistance and platinum-based chemotherapy alternatives. Computational methods, particularly molecular docking, are routinely employed alongside biological evaluation to understand the interaction between these metal complexes and biological targets. The recurring themes are the design of new coordination environments, the determination of solid-state structures, and the assessment of cytotoxicity against resistant cancer phenotypes.
The largest share of the community's output is found in platinum research, accounting for 19.6% of all platinum research, and 12,087 papers here. Ruthenium research follows with a 14.1% share, and cobalt research contributes 11.5% of its respective element's output.
The community comprises 74,648 papers, publishing primarily in Inorganic Chemistry, Inorganica Chimica Acta, and Polyhedron.
Recent work continues to explore the synthesis of new arylidene isatin hydrazones and ruthenium-based photocages for drug activation, alongside studies on osmium-platinum conjugates for photodynamic therapy in ovarian cancer.